Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

By Purmonen Timo T.   Päänkäälääinen Emma   Turunen Juha H. O.   Asseburg Christian   Martikainen Janne A.  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 344-352

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias   Wilking Nils   Jonsson Bengt   Rehnberg Clas  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast Cancer

By Ouagari Khalid   Karnon Jon   Delea Thomas   Talbot Willena   Brandman Jane  

Breast Cancer Research and Treatment, Vol. 101, Iss. 1, 2007-01 ,pp. : 37-49

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

By Lundkvist Jonas   Wilking Nils   Holmberg Stig   Jönsson Linus  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 289-299

Springer Publishing Company

Access to resources Recommend Favorite

Using Cost-Effectiveness Analysis to Define a Breast Cancer Benefits Package for the Uninsured

By Malin J.L.  

Breast Cancer Research and Treatment, Vol. 74, Iss. 2, 2002-07 ,pp. : 143-153

Springer Publishing Company

Access to resources Recommend Favorite